Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Subtherapeutic itraconazole and voriconazole levels in children with cystic fibrosis.

Bentley S, Gupta A, Balfour-Lynn IM.

J Cyst Fibros. 2013 Jul;12(4):418-9. doi: 10.1016/j.jcf.2012.09.007. Epub 2012 Oct 24. No abstract available.

2.

Pharmacokinetics of oral voriconazole in patients with cystic fibrosis.

Clifton IJ, Whitaker P, Metcalfe R, Phillip M, Shaw N, Conway SP, Peckham DG.

J Antimicrob Chemother. 2011 Oct;66(10):2438-40. doi: 10.1093/jac/dkr300. Epub 2011 Jul 25. No abstract available.

PMID:
21791443
4.

Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients.

Mohammedi I, Piens MA, Padoin C, Robert D.

Eur J Clin Microbiol Infect Dis. 2005 May;24(5):358-60. No abstract available.

PMID:
15875225
5.

Voriconazole pharmacokinetics and photosensitivity in children with cystic fibrosis.

Markantonis SL, Katelari A, Pappa E, Doudounakis S.

J Cyst Fibros. 2012 May;11(3):246-52. doi: 10.1016/j.jcf.2011.12.006. Epub 2012 Jan 28.

6.

High-dose voriconazole in a critically ill pediatric patient with neuroblastoma.

Alffenaar JW, Doedens RA, Groninger E, Kosterink JG.

Pediatr Infect Dis J. 2008 Feb;27(2):189-90. doi: 10.1097/INF.0b013e31815c89fd. No abstract available.

PMID:
18174859
7.

Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency.

Gerin M, Mahlaoui N, Elie C, Lanternier F, Bougnoux ME, Blanche S, Lortholary O, Jullien V.

Ther Drug Monit. 2011 Aug;33(4):464-6. doi: 10.1097/FTD.0b013e3182241b2b.

PMID:
21743382
8.

Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma.

Baietto L, D'Avolio A, Ventimiglia G, De Rosa FG, Siccardi M, Simiele M, Sciandra M, Di Perri G.

Antimicrob Agents Chemother. 2010 Aug;54(8):3408-13. doi: 10.1128/AAC.01807-09. Epub 2010 Jun 7.

9.

Voriconazole plasma monitoring.

Pasqualotto AC, Shah M, Wynn R, Denning DW.

Arch Dis Child. 2008 Jul;93(7):578-81. doi: 10.1136/adc.2007.118844. Epub 2008 Feb 5. Erratum in: Arch Dis Child. 2008 Oct;93(10):907.

PMID:
18252755
10.

Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age.

Shima H, Miharu M, Osumi T, Takahashi T, Shimada H.

Pediatr Blood Cancer. 2010 Jul 1;54(7):1050-2. doi: 10.1002/pbc.22451.

PMID:
20146339
11.

International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations.

Br├╝ggemann RJ, Touw DJ, Aarnoutse RE, Verweij PE, Burger DM.

Antimicrob Agents Chemother. 2009 Jan;53(1):303-5. doi: 10.1128/AAC.00901-08. Epub 2008 Nov 17.

12.

A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid.

Wiederhold NP, Pennick GJ, Dorsey SA, Furmaga W, Lewis JS 2nd, Patterson TF, Sutton DA, Fothergill AW.

Antimicrob Agents Chemother. 2014;58(1):424-31. doi: 10.1128/AAC.01558-13. Epub 2013 Nov 4.

13.

[A case of lung scedosporiosis successfully treated with monitoring of plasma voriconazole concentration level].

Ogata R, Hagiwara E, Shiihara J, Ogura T, Takahashi H, Kamei K.

Nihon Kokyuki Gakkai Zasshi. 2011 May;49(5):388-92. Japanese.

PMID:
21688649
14.

Plasma concentrations of voriconazole in falcons.

Schmidt V, Demiraj F, Di Somma A, Bailey T, Ungemach FR, Krautwald-Junghanns ME.

Vet Rec. 2007 Aug 25;161(8):265-8.

PMID:
17720963
15.

Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity.

Mitsani D, Nguyen MH, Shields RK, Toyoda Y, Kwak EJ, Silveira FP, Pilewski JM, Crespo MM, Bermudez C, Bhama JK, Clancy CJ.

Antimicrob Agents Chemother. 2012 May;56(5):2371-7. doi: 10.1128/AAC.05219-11. Epub 2012 Feb 13.

16.

Intravenous voriconazole after toxic oral administration.

Alffenaar JW, van Assen S, de Monchy JG, Uges DR, Kosterink JG, van der Werf TS.

Antimicrob Agents Chemother. 2010 Jun;54(6):2741-2. doi: 10.1128/AAC.01193-09. Epub 2010 Apr 12.

17.

An alternative approach to determine oral bioavailability of drugs that follow Michaelis-Menten elimination: a case study with voriconazole.

Verlindo de Araujo B, Farias da Silva C, Costa TD.

Pharmacology. 2010;86(3):163-7. doi: 10.1159/000317066. Epub 2010 Aug 13.

PMID:
20714206
18.

[Usefulness of monitoring plasma voriconazole concentration in patients with chronic necrotizing pulmonary aspergillosis].

Hagiwara E, Shiihara J, Matsushima A, Enomoto T, Tagawa A, Sekine A, Tsuchiya N, Baba T, Shinohara T, Endo T, Sogo Y, Nishihira R, Komatsu S, Kato T, Ogura T, Takahashi H.

Nihon Kokyuki Gakkai Zasshi. 2009 Feb;47(2):93-7. Japanese.

PMID:
19260530
19.

Voriconazole plasma levels in children are highly variable.

Spriet I, Cosaert K, Renard M, Uyttebroeck A, Meyts I, Proesmans M, Meyfroidt G, de Hoon J, Verbesselt R, Willems L.

Eur J Clin Microbiol Infect Dis. 2011 Feb;30(2):283-7. doi: 10.1007/s10096-010-1079-8. Epub 2010 Oct 21. No abstract available.

PMID:
20963460
20.

To treat or not to treat with antifungal agents?

Schoeni MH.

J Cyst Fibros. 2005 Dec;4(4):213-4. Epub 2005 Oct 25. No abstract available.

Supplemental Content

Support Center